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Decreased β-amyloid1−42 and increased phospho-tau protein levels in the cerebrospinal ﬂuid (CSF)are currently the most accurate
chemical neurodiagnostics of sporadic Alzheimer disease (AD). A report (2007) of the Third Canadian Consensus Conference on
the Diagnosis and Treatment of Dementia (2006) recommended that biological markers should not be currently requisitioned by
primary care physicians in the routine investigation of subjects with memory complaints. Consideration for such testing should
prompt patient referral to a specialist engaged in dementia evaluations or a Memory Clinic. The specialist should consider having
CSF biomarkers (β-amyloid1−42 and phospho-tau) measured at a reputable facility in restricted cases presenting with atypical
features and diagnostic confusion, but not as a routine procedure in all individuals with typical sporadic AD phenotypes. We
submit that developments in the ﬁeld of AD biomarker discovery since publication of the 3rd CCCDTD consensus data do not
warrant revision of the 2007 recommendations.
1.Introduction
The advent of a biological marker that reliably indicates the
presence of Alzheimer disease (AD) and distinguishes the
latter from other dementing disorders would greatly assist
the medical management of this commonneurodegenerative
condition. The successful integration of such a marker in
routine clinical practice would confer the following beneﬁts:
(1) the accurate and expeditious diagnosis of sporadic AD,
(2) curtailment of ancillary biochemical and imaging studies
currently employed to exclude other causes of dementia,
(3) the capacity to recognize AD in subjects with major
aﬀective disorders, clouded sensorium, depressed levels
of consciousness, and other illnesses that often preclude
assignment of a dementia diagnosis by conventional means,
(4) possible surveillance of AD severity, progression, and
impact of therapeutic interventions, (5) prognostication of
conversiontoincipientADinindividualswithmildcognitive
impairment (MCI), and (6) treatment arm assignment and
stratiﬁcation of volunteers enrolled in clinical trials. In this
paper, we review criteria for ideal biomarkers of sporadic
AD, chemical biomarkers currently in vogue, and a national
perspective on the clinical use of AD biomarkers in Canada
based on the Third Canadian Consensus Conference on the
Diagnosis and Treatment of Dementia [1].
2.Biological MarkersandSporadic AD
A biological marker of disease may be deﬁned as a measur-
able change in the physical composition of an organism that
indicates the presence of the illness. Biomarkers currently
under investigation for the early diagnosis of AD include
brain volume or activity measurements derived from neu-
roimaging techniques, such as positron emission tomogra-
phy (PET) or magnetic resonance imaging (MRI) and chem-
ical indices detected in various body ﬂuids. Neuroimaging
modalities are labor-intensive, expensive, and not universally
available, prompting intense research eﬀorts towards the
development of eﬀective chemical biomarkers and other
practical neurodiagnostic tools. Chemical markers of AD
fall within three general categories: (i) genetic markers, (ii)
genetic modiﬁers, and (iii) biological markers.M u t a n tf o r m s
of amyloid precursor protein, presenilin-1, and presenilin-
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predicting disease in rare kindreds with familial AD (<10%
of all AD cases), they play little or no role in tracking
disease progression or eﬃcacy of therapeutic intervention
in these patients. Moreover, these genetic markers have
little or no relevance for the management of individuals
with the far more common, sporadic form of the disease
[1, 2]. Carriers of the apolipoprotein E (APOE) ε4a l l e l e ,a
genetic modiﬁer, are at increased risk for the development
of sporadic AD, manifest dementia symptoms earlier than
ε4-negative persons with the disease, and exhibit accelerated
conversion rates from MCI to AD [3]. However, testing
for the ε4 allele cannot be used as a diagnostic marker of
sporadic AD because its presence does not guarantee that
that the disease exists or will occur nor does its absence
exclude the condition. True biological markers of AD, in
contradistinction to genetic markers and modiﬁers, inform
onthepresenceorabsenceofADatthetimeofmeasurement
(“state” indicators) and may therefore serve as diagnostic
modalities of the disease.
3. Criteriafor an “Ideal” Biological Marker of
SporadicAD
Principles set forth in a Consensus Report on Molecular and
Biochemical Markers of AD sponsored by the Alzheimer’s
Association (US) and the National Institute on Aging have
servedasaguidinglightforthedevelopmentofADbiomark-
ers worldwide [2]. This landmark report recommended that
an “ideal” biological marker of AD meet the following
criteria [4]:
(i) reﬂect a fundamental aspect of CNS pathophysiology
in AD (plausibility);
(ii) indicate the actual presence of AD and not merely
increased risk;
(iii) exhibithighsensitivityandspeciﬁcity(intherangeof
80% or better for each);
(iv) be eﬃcacious in early or preclinical AD (e.g., MCI);
(v) monitor disease severity or rate of progression;
(vi) indicate eﬃcacy of therapeutic intervention;
(vii) be noninvasive, inexpensive, and readily available.
In subsequent reports on this topic, it was also deemed
desirable that (viii) the eﬃcacy of the putative biomarker be
corroborated by at least one other independent laboratory
and that its accuracy (criterion (iii)) be demonstrated
in discriminating AD not only from cognitively-healthy
controls but from patients with various non-AD dementias
[5].
4.Biological MarkersofSporadicAD
In this section, we review the utility of CSF β-amyloid1–42
(Aβ1–42)andtau/phospho-tau(p-tau)measurementsasclin-
ical biomarkers of sporadic AD. Other candidate chemical
biomarkers of the disease currently commercially available
or under investigation include urine AD7C-neuronal thread
protein (marketed by Nymox Pharmaceutical Corp., Mon-
treal),CSF and urinary F2-isoprostanes, other redox reporter
molecules, plasma biospectroscopy, and a host of blood
proteins, mRNAs, microRNAs, cholesterol metabolites, and
transition metals. The latter will require further validation
before they can be recommended for routine clinical use
and will not be discussed further. Readers interested in these
candidate biomarkers may consult recent literature from the
author’s laboratory and others on this topic [1, 6–19].
(i) CSF Aβ1–42: Amyloid fragments are plausible AD
biomarkers because they represent a hallmark pathological
process in the aﬀected brain (senile plaque formation).
Evidence from numerous studies worldwide indicates that
concentrations of the amyloid peptide fragment Aβ1–42 are
abnormally diminished in the CSF of patients with sporadic
AD and MCI [19, 20]. A meta-analysis involving 18 studies
of CSF Aβ1–42 as a diagnostic marker of AD revealed an eﬀect
size of 1.56 (95% CI: 1.43–1.69) [21]. In 2003, an analysis
of CSF Aβ1–42 data derived from 13 studies (∼600 AD and
450 control subjects), all utilizing the Innogenetics ELISA for
the peptide, indicated an overall sensitivity and speciﬁcity
of 80% and 90%, respectively, for distinguishing AD from
cognitively-healthy controls [22]. However, CSF Aβ1–42 may
declineinotherdegenerativeCNSconditionsincludingLewy
body dementia (LBD) [23–25], amyotrophic lateral sclerosis
(ALS) [26], multisystem atrophy [27], and Creutzfeldt-Jakob
disease(CJD)[24,28].Thus,inamulticentrestudyinvolving
150 AD, 100 normal elderly controls and 79 cases of non-
AD dementia, the speciﬁcity of CSF Aβ1–42 in diﬀerentiating
AD from normal subjects was 81% whereas it was only
59% relative to non-AD dementias [29]. Important data
concerning the use of CSF biomarkers in the management
of AD are now emerging from the Alzheimer Disease
Neuroimaging Initiative (ADNI), a large, multi-institutional
prospective study designed to correlate clinical phenotypes
with imaging and chemical biomarkers in >800 rigorously-
ascertained subjects with normal cognition, MCI, and AD
[30] .Aﬁ r s ts u c hr e p o r t[ 31] conﬁrmed the stratiﬁcation
of cognitively normal, MCI and AD subjects based on
declines in CSF Aβ1–42 levels (205.6±55.1, 162.8 ±56.0, and
143.0 ± 40.8pg/ml for the 3 groups, respectively; P<. 001).
Moreover, baseline CSF Aβ1–42 concentrations successfully
predicted the deterioration of neuropsychological measures
in the normal and MCI cohorts (but not AD persons) over
an ensuing 12-month period. Plasma amyloid:a u g m e n t e d
plasma β-amyloid1–42 (Aβ1–42) concentrations have been
reported in several kindreds with familial AD [32], but these
families comprise a very small proportion of the entire AD
population. Measurements of CSF or blood total Aβ peptide,
Aβ1−40 or soluble APPα/β concentrations have thus far not
provenusefulinthediagnosisofsporadicAD[20,22,33–35]
although identiﬁcation of novel amyloid peptide fragments
inADbioﬂuidsusingmassspectrometrytechniquesmaystill
yield markers of diagnostic signiﬁcance [19, 36].
(ii) CSF total tau: CSF total (t) tau reﬂects neuroﬁbrillary
tangle formation in the AD brain but is also a fairly non-
speciﬁc marker for neuronal destruction in a wide range of
degenerative and nondegenerative CNS disorders. Elevated
levels of total tau protein (t-tau) have been consistentlyInternational Journal of Alzheimer’s Disease 3
e n c o u n t e r e di nA DC S F .A ne ﬀect size of 1.31 (95% CI:
1.23–1.39) for CSF tau as an AD diagnostic was disclosed
in a meta-analysis involving 35 studies [21]. In 2003, a
review of CSF t-tau data from 41 studies (over 4000 AD
and control subjects) that used either the Innogenetics or
Athena ELISA disclosed a sensitivity and speciﬁcity for the
diagnosis of AD of 80% and 90%, respectively (akin to the
meta-analysis of CSF Aβ1–42)[ 22]. In the robust ADNI study
[31], CSF t-tau increased progressively from 69.7 ± 30.4t o
101.4 ± 62.2 to 119.1 ± 59.6pg/ml in normal, MCI, and
AD subjects, respectively (P<. 001). As in the case of CSF
Aβ1–42, CSF t-tau is less eﬀective in discriminating AD from
other dementias, with speciﬁcities of 57% for suspected non-
AD dementias [29] and 69% for autopsy-conﬁrmed cases
[24]. Elevated concentrations of CSF t-tau may also predict
progression of cognitive deterioration in MCI, especially
in patients without extensive periventricular white matter
lesions[37].HighlevelsofCSFt-taumayalsoariseinfronto-
temporaldementia(FTD)[38],vasculardementia[39],CJD,
and (transiently) in acute ischemic stroke [40]. CSF t-tau
values in LBD [23] and vascular dementia [41]m a yb e
intermediatebetweenthoseofthecognitively-normalelderly
and subjects with AD. Interestingly, 34% of individuals
with FTD in one study exhibited signiﬁcantly suppressed
levels of CSF tau, a ﬁnding not seen in the AD cohort
[42].
(iii) CSF phospho-tau: Phospho-tau isoforms are ten-
able AD biomarkers because they reﬂect a known patho-
physiological process in AD brain (neuroﬁbrillary tangle
formation). A number of laboratories have documented
signiﬁcant increases in levels of hyperphosphorylated tau
in AD CSF relative to cognitively-intact controls using
antibodies against various phosphorylated epitopes of tau
(p-tau). CSF p-tau is elevated in “incipient AD” [43]a n d
MCI [44, 45] and is therefore a relatively early biomarker
of the disease. In the aforecited ADNI report [31], levels
of threonine 181 p-tau in the CSF of persons with normal
cognition, MCI, and AD were, respectively, 24.9 ± 14.6,
35.5 ± 18.0, and 41.6 ± 19.8pg/ml(P<. 001). Use of CSF
p-tau to monitor disease progression may be limited by
dilutional factors unless combined with MRI measurements
of hippocampal atrophy [46]. Of note, p-tau levels in AD
CSF are reportedly elevated relative to other dementing
and nondementing neurological disorders [22, 47, 48]. As
such, and in contradistinction to t-tau, enhanced CSF p-
tau levels may diﬀerentiate AD from FTD [49, 50], Lewy
body dementia [51], vascular dementia [52], PD [53], ALS,
acute stroke [54], schizophrenia [55], and major depression
[53]. Despite a previous report to the contrary [56], CSF
concentrations of threonine 181 p-tau may be augmented in
sporadic and variant CJD [57].
(iv) CSF Aβ1–42 and p-tau combined: CSF Aβ1–42 and
p-tau, when measured together, exhibit sensitivities and
speciﬁcities (versus other dementing disorders) in the range
of 80%–90% [58]. The positive and negative predictive
values of the combined test are 90% and 95%, respectively,
assuming a prevalence rate of 45% [20]. This biomarker
combination reﬂects disease pathophysiology (vide supra),
i d e n t i ﬁ e sA Di ne a r l ys t a g e s( e . g . ,M C I ) ,a n di sr e l a t i v e l y
inexpensive. Some posit that CSF Aβ1–42 represents the
stage of AD (with concentrations diminishing progressively
as a function of disease duration), while t-tau and p-
tau are indicators of disease intensity (with higher CSF
levels connoting more rapid progression) [59]. It has been
suggested that the extent of CSF tau elevation and Aβ1–42
suppression may correlate with the APOE ε4a l l e l eb u r d e n
[60] although the extent to which genetic factors impact CSF
biomarker levels remains uncertain. In patients with MCI,
the biomarker combination may prognosticate for imminent
conversion to AD with sensitivities/speciﬁcities in the range
of 83%–90% [61, 62]. The markers also exhibited eﬃcacy
in delineating “nonprogressors” in “mixed” (amnestic and
nonamnestic) MCI over a 3-year median follow-up period
[63] and may assist in distinguishing MCI from anxiety
and depression [64]. A large European-American multi-
institutional trial employed a cutoﬀ CSF Aβ1–42/p-tau ratio
predetermined from an established AD cohort (at 85%
sensitivity) to detect AD in 750 MCI individuals followed
longitudinally for at least two years or until dementia
intervened. The investigators identiﬁed incipient AD in the
MCI subjects with 83% sensitivity, 72% speciﬁcity, 62%
positive predictive value, and 88% negative predictive value.
The authors concluded that although the test was accurate
in identifying incipient AD, intersite assay variability limited
its performance relative to previous results from single-
centre studies, underscoring the need for standardization of
clinicalproceduresandanalyticaltechniques[65].Inanother
recent multicentre study, AD-like CSF biomarker ratios were
notedtobemorefrequentamongindividualswithsubjective
(but no objective) cognitive impairment (SCI; 52%) than in
healthy controls (31%; P<. 01), suggesting that AD may
be the cause of SCI (and not only MCI) in a signiﬁcant
proportion of elderly subjects [66]. To our knowledge, CSF
Aβ1–42 and tau determinations have not yet proven helpful as
indices of therapeutic eﬃcacy in AD.
(v) CSF biomarkers: further considerations: (a) In the
majority of AD biomarker studies, the validity of the
data were limited because receiver operating characteris-
tic curves (plotting the relationship between sensitivities
and speciﬁcities) were generated on the basis of clinical
diagnoses without autopsy corroboration. While prospective
AD biomarker studies are in principle more valuable than
retrospective analyses, the former are less likely to include
neuropathological diagnoses [67]. (b) The immunoassay
procedures invoked to measure CSF Aβ1–42 and tau are not
trivial, and interlaboratory variability is commonplace. (c)
Athena Neurosciences charges US$905 to MDs and $1,335
to insurance companies for the combined tau and CSF
Aβ1–42 assays per sample. It was announced this year that the
cost of AD biomarkers would be defrayed by the Canadian
government pending documentation of need. Regardless,
the cost may not be prohibitive if it obviates the need for
additional testing (e.g., neuroimaging). (d) In a study of 342
AD, MCI, and cognitively normal individuals subjected to
428 research lumbar punctures, the adverse eﬀect rate was
low (e.g., post-LP headaches in 0.93%), and the procedure
was generally well tolerated (low pain and anxiety scores
in visual analog scales) [68]. Yet, CSF examination by4 International Journal of Alzheimer’s Disease
lumbar puncture is more invasive than venipuncture or
urine analysis and currently not suitable for mass screening
of elderly persons with AD risk factors or mild memory
impairment. The latter could warrant revisiting in the event
that eﬀective measures to prevent AD were to become
available.
5. The Third CanadianConsensus Conference
on the Diagnosis andTreatment of Dementia
Canadian Consensus Conferences on the Diagnosis and
Treatment of Dementia were held in 1989, 1998 and,
most recently, in March 2006 (Montreal) in attempt to
standardize the diagnostic and therapeutic management
of AD and related dementias in our country [69]. The
structure and organization of the 3rd CCCDTD followed
guidelines of the AGREE collaboration [70]. The project
was funded by major government health institutes, geriatric
and Alzheimer societies, and unrestricted grants from the
pharmaceuticalindustry.Acknowledgedleadersrepresenting
the disciplines of neurology, geriatric medicine, geriatric
psychiatry, and neuropsychology, with liaisons from family
practice, participated in the 3rd CCCDTD. PubMed and
Embase electronic databases (supplemented by individual
investigator ﬁles) spanning from January 1996 to December
2005 were surveyed for pertinent literature on nine desig-
nated topics. Publications were included for review based
on their quality as determined by Jadad criteria [71]. The
strength of evidence was graded according to the Canadian
Task Force on Preventive Health Care [72]:
(I) Evidence obtained from at least one properly ran-
domized controlled trial. (II-1) Evidence obtained from
well-designed controlled trials without randomization, (II-
2) Evidence obtained from well-designed cohort or case-
control analytic studies preferably from more than one
centre or research group, or (II-3) evidence obtained from
comparisons between times or places with or without the
intervention. Dramatic results in uncontrolled experiments
are included in this category. (III) Opinions of respected
authorities based on clinical experience, descriptive studies,
or reports of expert committees. The valence and strength
of recommendations were assigned using the following
grading system [73, 74]. (A) There is good evidence
to support this maneuver. (B) There is fair evidence to
support this maneuver. (C) There is insuﬃcient evidence
to recommend for or against this maneuver, but recom-
mendations might be made on other grounds. (D) There
is a fair evidence to recommend against this procedure.
(E) There is good evidence to recommend against this
procedure. Background papers and sets of recommendations
for each topic were posted online and voted upon by
all conferees. Recommendations receiving at least 80%
support were considered to have achieved consensus. The
full list of approved recommendations is available on the
websites of the 3rd CCCDTD (http://www.cccdtd.ca/)a n d
theAlzheimerSocietyofCanada(http://www.alzheimer.ca/).
Eighteen background articles accruing from this exercise
were published in the October 2007 issue of Alzheimer’s &
Dementia.
6. 3rd CCCDTD: Role of Biomarkers
To ascertain the role of biomarkers in AD for the 3rd
CCCDTD, the author reviewed a total of 186 papers: 137
generated from surveillance of the electronic literature (see
Section 5) using the search terms “Alzheimer disease” AND
(“Biological Marker” OR “Biomarker”), and an additional
49 articles from the author’s ﬁles. The analysis led to the
following conclusions [1]
(i)ADisapublichealthconcernofepidemicproportions
for which current diagnostic (and therapeutic) modalities
remain insuﬃcient.
(ii) The advent of a biological marker that diﬀeren-
tiates early, sporadic AD from normal aging and other
dementing disorders would represent a signiﬁcant advance
in the evaluation and management of this neurodegenerative
disorder. An accurate, minimally invasive biological marker
of early sporadic AD would serve the public interest by
facilitating patient and family counselling, enabling strati-
ﬁcation of subgroups for enrolment in clinical drug trials,
and improving the interpretation of treatment outcomes.
The introduction of a chemical marker that diﬀerentiates
“malignant” MCI cases at high risk for deterioration to
AD from neuropsychologically similar cases destined to
manifest “benign” aging-associated memory changes would
be particularly useful. Biomarkers may also prove helpful
in situations where concomitant medical or psychiatric
conditionsconfoundorprecludeneuropsychologicaltesting,
for example, major depression, delirium, suppressed con-
sciousness, or individuals who are otherwise uncooperative
for detailed cognitive testing. (Although conjectural and
not listed among the published conclusions of the 3rd
CCCDTD, it should prove interesting to determine whether
measurement of AD biomarkers in patients with normal
pressure hydrocephalus assists in the selection of appropriate
candidates for (and improves the success rate of) surgical
shunting.)
(iii) Although several candidate biomarkers of sporadic
AD have been identiﬁed and commercialized, none currently
fulﬁlls criteria for an ideal test (see Section 3).
(iv)DecreasedAβ1–42 andincreasedphospho-tauprotein
concentrations in the CSF are currently the most accurate
and reproducible chemical neurodiagnostics of sporadic AD.
These biomarkers also show promise as prognosticators in
subjects with MCI. However, CSF evaluation by spinal tap
remains impractical for mass screening of elderly individ-
uals with symptoms of memory impairment or AD risk
factors.
(v) Platelet APP isoform ratios, plasma or urinary
F2-isoprostane levels, blood biospectroscopy, and other
modalities under investigation may fulﬁl several criteria for
an “ideal” biological marker of early sporadic AD (Sec-
tion 3). However, further experimentation and validation
will be needed before these candidate biomarkers can be
considered for clinical use. Similarly, all AD biomarker
candidates arising from mass spectrometry and other
proteomic applications [19, 75, 76] will require stringent
clinical evaluation for their suitability as bonaﬁde diagnostic
tools.International Journal of Alzheimer’s Disease 5
(vi) Given the complexity of AD pathology, it is likely
that combinations of individual biomarkers will provide
more accurate diagnostic and prognostic data that any
single marker assayed in isolation (akin to use of multiple
biochemical indices to characterize liver failure, cardiac
ischemia, or connective tissue disease).
Onthebasisoftheliteratureanalysisandaforementioned
conclusions, the following recommendations reached consen-
sus (see Section 5) and were published by the 3rd CCCDTD
[1].
6.1. To Primary Care Physicians. (i) “Biological markers
for the diagnosis of AD should not, at this juncture, be
included in the battery of tests routinely used by primary
carephysicianstoevaluatesubjectswithmemoryloss(Grade
C, Level 3). Consideration for such specialized testing in
an individual case should prompt referral of the patient to
a specialist engaged in dementia evaluations or a Memory
Clinic.”
6.2. To Specialists. (i) “Although highly desirable, there
currently exist no blood- or urine-based AD diagnostics that
can be unequivocally endorsed for the routine evaluation
of memory loss in the elderly (Grade C, Level 3). The
non-invasiveness of such tests, if and when they become
available, would be suitable for mass screening of subjects
withmemorylosspresentingtospecialistsintheiroﬃcesand
Memory Clinics.
(ii) Due to their relative invasiveness and availability
of other fairly accurate diagnostic modalities (clinical, neu-
ropsychological and neuroimaging), CSF biomarkers should
not be routinely performed in all subjects undergoing
evaluation for memory loss (Grade D, Level 2).
(iii) CSF biomarkers may be considered in cases where
there are atypical features and diagnostic confusion. CSF
biomarkers may be useful in diﬀerentiating frontal variants
of AD from FTD (Grade B, Level 2).
(iv) When a decision to obtain CSF biomarkers is
made, combined Aβ1–42 and p-tau concentrations should be
measured by validated ELISA (Grade A, Level 1). It may
be best to convey the CSF samples to a centralized facility
(commercial or academic) with a track record in generating
high-quality, reproducible data.
(v) CSF biomarker data in isolation are insuﬃcient
to diagnose or exclude AD (Grade C, Level 3). They
should be interpreted in light of clinical, neuropsychological,
other laboratory and neuroimaging data available for the
individual under investigation.”
It is the opinion of the author and Dr. Howard Chertkow
(Chair, 3rd CCCDTD, personal communication) that devel-
opments reported in the ﬁeld of AD biomarker discovery
since publication of the 3rd CCCDTD consensus data do
not warrant revisal of the 2007 recommendations. However,
this remains an area of intensive research worldwide and
further insights from large-scale initiatives such as ADNI, or
validation of blood- or urine-based markers of the disease,
may prompt a sea-change in the way AD biomarkers are
exploited in Canadian clinics.
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